NuCana (NASDAQ:NCNA) announced its quarterly earnings results on Tuesday. The company reported ($12.00) EPS for the quarter, topping analysts’ consensus estimates of ($18.20) by $6.20, Yahoo Finance reports.
NCNA opened at $6.11 on Friday. The stock has a fifty day simple moving average of $5.58 and a two-hundred day simple moving average of $5.94. The company has a current ratio of 10.19, a quick ratio of 10.54 and a debt-to-equity ratio of 0.01. The company has a market cap of $239.37 million, a price-to-earnings ratio of -7.73 and a beta of 1.08. NuCana has a 12-month low of $3.81 and a 12-month high of $16.00.
A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of NuCana in a research note on Tuesday. ValuEngine downgraded NuCana from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 3rd. Finally, Zacks Investment Research upgraded NuCana from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $15.63.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer.
Read More: Analyst Ratings
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.